Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

Kim A Connelly; Deepak L Bhatt; Subodh Verma

doi:10.1016/j.cmet.2018.11.010

Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?

Cell Metab. 2018 Dec 4;28(6):813-815. doi: 10.1016/j.cmet.2018.11.010.

Authors

Kim A Connelly¹, Deepak L Bhatt², Subodh Verma³

Affiliations

¹ Division of Cardiology, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada.
² Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
³ Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Departments of Surgery, and Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: vermasu@smh.ca.

PMID: 30517896
DOI: 10.1016/j.cmet.2018.11.010

Abstract

Heart failure and renal disease remain significant complications in people with type 2 diabetes (T2D). Recent outcome studies with sodium-glucose cotransporter-2 (SGLT2) inhibitors have provided increasing insights, with the latest reporting trial DECLARE-TIMI 58 (Wiviott et al., 2018), pointing toward a role for these agents in the primary prevention of cardio-renal complications in T2D.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Benzhydryl Compounds
Diabetes Mellitus, Type 2*
Glucosides
Humans
Hypoglycemic Agents

Substances

Benzhydryl Compounds
Glucosides
Hypoglycemic Agents
dapagliflozin

Grants and funding

CIHR/Canada